In a packed session at the International Society for Stem Cell Research (ISSCR) 2026 Annual Meeting, a California biotech firm unveiled clinical data that could reset the conversation around cell replacement therapies for type 1 diabetes. Encellin reported that all seven participants in its first-in-human trial of an implantable “living drug” achieved durable, non-fibrotic engraftment of donor islets without any need for lifelong immunosuppression. The announcement marks the first time that a subcutaneous implant has consistently dodged the foreign body response—the formation of a dense collagenous scar that starves and kills transplanted cells—while simultaneously recruiting host blood vessels into the device.
Type 1 diabetes destroys insulin-producing beta cells, and replacing them via islet transplantation has long been a tantalizing goal. However, two towering barriers have kept the strategy from becoming a routine treatment. First, the recipient’s immune system attacks the foreign cells, requiring chronic immunosuppressive drugs that come with serious side effects. Second, even if immune rejection is dampened, the body walls off a naked implant with a fibrotic capsule, cutting off oxygen and nutrients before the cells can establish a new blood supply. Encellin’s platform, called Encapsulated Cell Replacement Therapy (ENCRT), attempts to solve both problems with a single bioengineered device. The implant envelops allogeneic islets in a semipermeable membrane that physically shields them from immune cells and antibodies while permitting the free exchange of glucose, insulin, and other small molecules. Crucially, the membrane architecture and its surface chemistry are tuned to encourage host capillaries to grow right up against the encapsulated cells, forming an intimate vascular network that sustains long-term graft function.
The Phase 1 open-label study enrolled seven adults with established type 1 diabetes who would otherwise have met the criteria for standard-of-care islet transplantation. Each received a subcutaneous ENCRT implant loaded with human islets from deceased donors. The primary endpoint was safety and tolerability, not efficacy, and the trial was not designed to measure insulin independence. Nevertheless, the correlative science readouts have electrified the field. Across all seven recipients, explanted devices and imaging analyses demonstrated the complete absence of a fibrotic rind around the implant. Instead, histological sections revealed a rich lacework of host-derived microvessels penetrating the device periphery, with identifiable clusters of insulin-positive islets still viable at the time of analysis. The new dataset builds on interim results first reported in January 2026, expanding the evidence base to the full enrolled cohort.
“The field has made important advances in developing insulin-producing cells but delivering those cells safely and durably without lifelong immunosuppression remains one of the central challenges,” said Crystal Nyitray, Ph.D., CEO and Founder of Encellin. “These clinical findings represent encouraging progress toward addressing that challenge and provide evidence that our approach may support engraftment and vascularization without the fibrotic response that has historically limited implanted cell therapies.”
Avoiding fibrosis is no small feat. The foreign body response is an ancient, conserved wound-healing cascade that culminates in activated myofibroblasts laying down a dense collagen matrix. Most polymer encapsulation designs trigger this cascade within weeks, suffocating the therapeutic payload. While the exact mechanism behind ENCRT’s stealth is not fully public, investigators point to submicron-scale modifications in the membrane topography that alter protein adsorption and subsequent macrophage polarization, steering the immune system toward a pro-regenerative rather than a pro-fibrotic state. The device appears to achieve what materials scientists have sought for decades: a biointerface that is simultaneously immunoprotective, pro-angiogenic, and invisible to the fibrotic machinery.
Beyond the immediate diabetes application, the ENCRT platform is designed to be cell-agnostic. That opens the door to loading it with stem cell-derived beta cells, which can be manufactured at scale, thereby circumventing the scarcity of donor pancreata. Encellin has already disclosed early-stage programs in parathyroid disorders and other hormone-deficiency diseases where a robust, off-the-shelf cell therapy would transform the standard of care. The company’s backers—including Khosla Ventures and Endurance 28—see a future in which a single implantable device can deliver precise, pulsatile doses of missing proteins or peptides without the need for repeated injections or immune suppression.
Still, the present data remain early and open-label. Full analysis of the complete Phase 1 dataset is ongoing, and the findings will require replication in larger, controlled studies that include prespecified efficacy endpoints such as C-peptide levels and time-in-range glycemic metrics. The implant must also prove its durability over months to years, not just weeks. Safety signals, including any subtle immune sensitization, will be scrutinized. Yet for the diabetes research community, which has weathered many fits and starts in the pursuit of a functional cure, the complete absence of fibrosis and the presence of host vessels in all seven participants represent a milestone that had felt stubbornly out of reach.
The ISSCR audience greeted the presentation with a mix of cautious optimism and open curiosity. Several attendees noted that if the technology can be married to emerging sources of unlimited, gene-edited hypoimmune stem cells, the combination could finally deliver a scalable, immunosuppression-free cure for type 1 diabetes—and much more besides.
Subject of Research: Non-fibrotic engraftment and host vascularization of an implantable encapsulated cell therapy platform in adults with type 1 diabetes
Article Title: No Fibrosis, No Immunosuppression: A New Cell Implant Shows Promise in Type 1 Diabetes
News Publication Date: 2026
Web References: www.isscr2026.org ; www.encellin.com
References: Encellin clinical update presented at the ISSCR 2026 Annual Meeting; ISSCR 2026 program
Image Credits:
Keywords: Type 1 diabetes, Encapsulated Cell Replacement Therapy, ENCRT, fibrosis, foreign body response, vascularization, allogeneic islets, immunosuppression-free cell therapy, stem cell research, clinical research
